Pfizer and Biontech expand study of vaccines for children

The New York Times reports that vaccine studies involving children aged 5-11 will be made more comprehensive in the wake of a request from the FDA.

Photo: Dado Ruvic/REUTERS / X02714

Vaccine trials for children aged 5-11 should be more comprehensive. For this reason, studies of the Pfizer-Biontech vaccine and the Moderna vaccine within this group will now be expanded, writes the New York Times.

The US Food and Drug Administration have called for this to happen, asking vaccine companies to include 3,000 people in the trials, which is twice as many as originally planned, according to the NYT.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs